Efficacy and safety of GZR18 injected every 2 weeks (Q2W) in participants without type 2 diabetes, who have obesity or are overweight: a randomized, tirzepatide- and placebo-controlled study
This study will look at how an investigational drug called GZR18 works in your body by:
“Toku” Toku Inc / “CLAiR Pivotal Study”
Atherosclerotic Cardiovascular Disease (ASCVD) is a type of heart disease that happens when plaque builds up in the arteries, resulting in risk for a heart attack or stroke. ASCVD is the most common type of cardiovascular disease in the United States, and ASCVD is also the leading cause of death for people of most racial/ethnic […]
A Phase III double-blind, randomized, parallel-group superiority trial to evaluate efficacy and safety of the combined use oforal BI 690517 and empagliflozin compared with placebo andempagliflozin in participants with symptomatic heart failure (HF: NYHAII-IV) and left ventricular ejection fraction (LVEF) ≥40%.
The purpose of this clinical research trial is to look at the effectiveness, safety, and tolerance of combining the investigational trial drug called BI 690517 with empagliflozin (empa) in participants diagnosed with heart failure (HF). Empagliflozin is approved by the FDA for the treatment of heart failure. In this trial, the investigational new treatment option […]
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index (BMI) ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (TRIUMPH OUTCOMES)
This study is being done to see how safe an investigational drug is and how well it will work to help people with Body Mass Index (BMI) of greater than or equal to 27 kg/m2 and heart related and/or kidney related disease. “Investigational” means that the drug being tested has not been approved for routine […]
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
This trial is testing an experimental drug called MK-0616 in people with high cardiovascular risk. The purpose of this trial is to: A placebo looks like the trial drug, but it has no active ingredients.
